Table 3 Recurrence sites by treatment group

From: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation

Sites of recurrence

ASCT

MT

P-value

Intention to treat

% of 149 patients

% of 146 patients

 

All recurrences

54

63

0.156

Primary tumour

26

31

0.365

Metastases

50

57

0.727

Osteomedullary

34

34

0.847

Bone marrow

23

21

0.607

CNS*

10

13

0.325

Lymph nodes

5

6

1.000

Liver

6

<1

0.008

Other

<1

<1

1.000

As treated

% of 110 patients

% of 102 patients

 

All recurrences

48

72

0.001

Primary tumour

24

39

0.018

Metastases

38

53

0.038

Osteomedullary

29

36

0.820

Bone marrow

18

21

1.000

CNS*

14

12

0.365

Lymph nodes

4

7

0.542

Liver

6

2

0.132

Other

<1

<1

1.000

Treated as randomised

% of 75 patients

% of 70 patients

 

All recurrences

47

73

0.002

Primary tumour

21

39

0.029

Metastases

40

56

0.068

Osteomedullary

28

40

0.540

Bone marrow

16

20

0.460

CNS*

11

13

0.473

Lymph nodes

4

10

0.283

Liver

7

0

0.013

Other

1

1

0.684

Back to article page